The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Lepekhova S.A.

Irkutsk Scientific Center of Siberian Branch of the Russian Academy of Sciences

Kireeva V.V.

Irkutsk Research Center of Siberian Brunch of the Russian Academy of Science

Inozemtsev P.O.

Irkutsk Scientific Center of Siberian Branch of the Russian Academy of Sciences

Grigoriev G.E.

Irkutsk Scientific Center of Siberian Branch of the Russian Academy of Sciences

Korobeynikova L.V.

Irkutsk Scientific Center of Siberian Branch of the Russian Academy of Sciences

Mansurova L.N.

Irkutsk Scientific Center of Siberian Branch of the Russian Academy of Sciences

Kukushkina L.Yu.

Irkutsk Scientific Center of Siberian Branch of the Russian Academy of Sciences

Development of herd protection in older people in the context of universal COVID-19 vaccination

Authors:

Lepekhova S.A., Kireeva V.V., Inozemtsev P.O., Grigoriev G.E., Korobeynikova L.V., Mansurova L.N., Kukushkina L.Yu.

More about the authors

Journal: Russian Journal of Preventive Medicine. 2023;26(12): 41‑45

DOI: 10.17116/profmed20232612141

Read: 1257 times

Download PDF (RU)
Contact the author
Table of contents

DEVELOPMENT OF HERD PROTECTION IN OLDER PEOPLE IN THE CONTEXT OF UNIVERSAL COVID-19 VACCINATION
DEVELOPMENT OF HERD PROTECTION IN OLDER PEOPLE IN THE CONTEXT OF UNIVERSAL COVID-19 VACCINATION

To cite this article:

Lepekhova SA, Kireeva VV, Inozemtsev PO, Grigoriev GE, Korobeynikova LV, Mansurova LN, Kukushkina LYu. Development of herd protection in older people in the context of universal COVID-19 vaccination. Russian Journal of Preventive Medicine. 2023;26(12):41‑45. (In Russ.)
https://doi.org/10.17116/profmed20232612141

Подписка 2026 Профилактическая медицина (Russian Journal of Preventive Medicine)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
«One Health» approach: a comprehensive approach to human, animal and envi­ronmental health. Russian Journal of Preventive Medi­cine. 2024;(11):7-12
Factors of adhe­rence to vaccination of the Arkhangelsk region adult popu­lation. Russian Journal of Preventive Medi­cine. 2024;(12):92-99
Long-term outcomes in patients after hospital treatment for COVID-19 (three-year follow-up data). Russian Journal of Preventive Medi­cine. 2024;(12):114-121
Loca­lization features of FAP-positive acti­vated stro­mal cells in fibrosis in patients with new coro­navirus infe­ction COVID-19. Russian Journal of Archive of Pathology. 2024;(6):5-14
The role of drug Cyto­flavin in the correction of dysautonomia in patients with post-COVID syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):140-146
Lapa­roscopic appe­ndectomy for appe­ndiceal muco­cele in a patient with COVID-19. Endo­scopic Surgery. 2024;(6):41-45
Sele­ctive anosmia for mono­molecular odorants in a cohort of young indi­viduals. Russian Rhinology. 2024;(4):262-268
The resu­lts of the examination of patients with chro­nic gene­ralized periodontitis after novel coro­navirus infe­ction. Russian Journal of Stomatology. 2024;(4):18-22
Immu­nomodulatory therapy in the postoperative period in chro­nic puru­lent otitis media. Russian Bulletin of Otorhinolaryngology. 2024;(6):10-17
Anti­fungal immu­nity in patients with chro­nic rhinosinusitis with nasal polyps. Russian Bulletin of Otorhinolaryngology. 2024;(6):40-45
Abstract:

To predict the progression of the epidemiological situation and plan measures for the specific and non-specific prevention of COVID-19, studies of herd immunity to SARS-CoV-2 are necessary. According to the literature, the threshold level of herd immunity necessary for the extinction of some infections is 60-70%.

OBJECTIVE

To determine the level and structure of herd immunity to SARS-CoV-2 in the older age group during the universal vaccination against COVID-19.

MATERIAL AND METHODS

The study was performed in the Department of Biomedical Research and Technology of the Research Center of the Irkutsk Scientific Center of Siberian Branch of the Russian Academy of Sciences (ISC SB RAS). The study protocol included 192 people who are employees of ISC SB RAS, including 64 people of the older age group (65+). The age of the subjects varied from 20 to 87 years.

RESULTS

The highest rates of herd immunity to the SARS-CoV-2 among the studied personnel of the ISC SB RAS were 77%. The highest level of seroprevalence of 83.5% was detected in subjects of the age group of 60-80 years. No SARS-CoV-2 IgM antibodies were detected in the study subjects after vaccination against the new coronavirus infection. In a comparative study of specific IgG antibodies, no statistically significant differences were found between vaccinated subjects and those with a history of COVID-19.

CONCLUSION

Further studies, monitoring, and control of antibody levels are needed to determine the optimal timeframe for booster vaccination or the development of an immunorehabilitation program for COVID-19 survivors.

Keywords:

COVID-19
immunity
vaccination
public health

Authors:

Lepekhova S.A.

Irkutsk Scientific Center of Siberian Branch of the Russian Academy of Sciences

Kireeva V.V.

Irkutsk Research Center of Siberian Brunch of the Russian Academy of Science

Inozemtsev P.O.

Irkutsk Scientific Center of Siberian Branch of the Russian Academy of Sciences

Grigoriev G.E.

Irkutsk Scientific Center of Siberian Branch of the Russian Academy of Sciences

Korobeynikova L.V.

Irkutsk Scientific Center of Siberian Branch of the Russian Academy of Sciences

Mansurova L.N.

Irkutsk Scientific Center of Siberian Branch of the Russian Academy of Sciences

Kukushkina L.Yu.

Irkutsk Scientific Center of Siberian Branch of the Russian Academy of Sciences

Received:

17.07.2023

Accepted:

24.07.2023

Close metadata

References:

  1. Gerasimov A, Lebedev G, Lebedev M, Semenycheva I. COVID-19 Dynamics: A Heterogeneous Model. Frontiers in Public Health. 2021;8:558368. https://doi.org/10.3389/fpubh.2020.558368
  2. Du M. Mitigating COVID-19 on a small-world network. Scientific Reports. 2021;11(1):20386. https://doi.org/10.1038/s41598-021-99607-z
  3. Khalirakhmanov AF, Idrisova KF, Gaifullina RF, et al. Pathogenesis, Diagnosis, and Treatment of Hemostatic Disorders in COVID-19 Patients. Acta Naturae. 2021;13(2):79-84.  https://doi.org/10.32607/actanaturae.11182
  4. Martsevich SY. Treatment of Patients with COVID-19 and Concomitant Cardiovascular Diseases: Do not Forget About the Principles of Evidence-based Medicine. Rational Pharmacotherapy in Cardiology. 2020;16(2):273-276.  https://doi.org/10.20996/1819-6446-2020-04-11
  5. Tsai PH, Lai WY, Lin YY, et al. Clinical manifestation and disease progression in COVID-19 infection. Journal of the Chinese Medical Association: JCMA. 2021;84(1):3-8.  https://doi.org/10.1097/JCMA.0000000000000463
  6. Kutyrev VV, Popova AYu, Smolensky VYu, et al. Epidemiological Features of New Coronavirus Infection (COVID-19). Communication 1: Modes of Implementation of Preventive and Anti-Epidemic Measures. Problemy osobo opasnykh infektsij. 2020;1:6-13. (In Russ.).
  7. Anastassopoulou C, Russo L, Tsakris A, Siettos C. Data-based analysis, modelling and forecasting of the COVID-19 outbreak. PLoS One. 2020;15(3): e0230405. https://doi.org/10.1371/journal.pone.0230405
  8. Rabaan AA, Al-Ahmed SH, Al-Malkey M, et al. Airborne transmission of SARS-CoV-2 is the dominant route of transmission: droplets and aerosols. Le Infezioni in Medicina. 2021;29(1):10-19. 
  9. Soriano-Arandes A, Gatell A, Serrano P, et al. Household severe acute respiratory syndrome coronavirus 2 transmission and children: A network prospective study. Clinical Infectious Diseases. 2021;73(6):e1261-e1269. https://doi.org/10.1093/cid/ciab228
  10. Johansson MA, Quandelacy TM, Kada S, et al. SARS-CoV-2 Transmission From People Without COVID-19 Symptoms. JAMA Network Open. 2021; 4(1):e2035057. https://doi.org/10.1001/jamanetworkopen.2020.35057
  11. Lai CC, Liu YH, Wang CY, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. Journal of Microbiology, Immunology, and Infection. 2020;53(3):404-412.  https://doi.org/10.1016/j.jmii.2020.02.012
  12. Iwasaki M, Saito J, Zhao H, et al. Inflammation Triggered by SARS-CoV-2 and ACE2 Augment Drives Multiple Organ Failure of Severe COVID-19: Molecular Mechanisms and Implications. Inflammation. 2021;44(1):13-34.  https://doi.org/10.1007/s10753-020-01337-3
  13. Devaux CA, Rolain JM, Raoult D. ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. Journal of Microbiology, Immunology, and Infection. 2020; 53(3):425-435.  https://doi.org/10.1016/j.jmii.2020.04.015
  14. Arshad Ali S, Baloch M, Ahmed N, et al. The outbreak of Coronavirus Disease 2019 (COVID-19) — An emerging global health threat. Journal of Infection and Public Health. 2020;13(4):644-646. 
  15. Ioannidis JPA. Global perspective of COVID-19 epidemiology for a full-cycle pandemic. European Journal of Clinical Investigation. 2020;50(12):e13423. https://doi.org/10.1111/eci.13423
  16. Li CH, Chiou HC, Lin MH, et al. Immunological map in COVID-19. Journal of Microbiology, Immunology, and Infection. 2021;54(4):547-556.  https://doi.org/10.1016/j.jmii.2021.04.006
  17. Tay MZ, Poh CM, Rénia L, et al. The trinity of COVID-19: immunity, inflammation and intervention. Nature Reviews. Immunology. 2020;20(6): 363-374.  https://doi.org/10.1038/s41577-020-0311-8
  18. Samprathi M, Jayashree M. Biomarkers in COVID-19: An Up-To-Date Review. Frontiers in Pediatrics. 2021;8:607647. https://doi.org/10.3389/fped.2020.607647
  19. Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. Journal of Thrombosis and Haemostasis: JTH. 2020;18(7): 1559-1561. https://doi.org/10.1111/jth.14849
  20. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135:2033-2040. https://doi.org/10.1182/blood.2020006000
  21. Deshpande C. Thromboembolic findings in COVID-19 autopsies: pulmonary thrombosis or embolism? Annals of Internal Medicine. 2020;173(5): 394-395.  https://doi.org/10.7326/M20-3255
  22. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta analysis. Clinica Chimica Acta; International Journal of Clinical Chemistry. 2020;506: 145-148.  https://doi.org/10.1016/j.cca.2020.03.022
  23. Ali S, Mathew S, Pappachan JM. Acute cor pulmonale from saddle pulmonary embolism in a patient with previous COVID-19: should we prolong prophylactic anticoagulation? International Journal of Infectious Diseases: IJID. 2020;97:299-302.  https://doi.org/10.1016/j.ijid.2020.06.039
  24. Arutyunov GP, Tarlovskaya EI, Arutyunov AG, et al. International register “Dynamics analysis of comorbidities in SARS-CoV-2 survivors” (AKTIV SARS-CoV-2): analysis of 1,000 patients. Rossijskij kardiologicheskij zhurnal. 2020;25(11):4165. (In Russ.). https://doi.org/10.15829/29/1560-4071-2020-4165
  25. Korostovtseva LS, Rotar OP, Konradi AO. COVID-19: what are the risks in hypertensive patients? Arterial’naya gipertenziya. 2020;26(2):124-132. (In Russ.). https://doi.org/10.18705/1607-419X-2020-26-2-124-132
  26. Azevedo RB, Botelho BG, Hollanda JVG, et al. Covid-19 and the cardiovascular system: A comprehensive review. Journal of Human Hypertension. 2021;35(1):4-11.  https://doi.org/10.1038/s41371-020-0387-4
  27. Balakhonov SV, Chesnokova MV, Perezhogin AN, et al. Epidemiological Situation on COVID-19 in Irkutsk Region and Forecast for its Spread. Problemy osobo opasnykh infektsij. 2020;4:34-40. (In Russ.). https://doi.org/10.21055/0370-1069-2020-4-34-40
  28. Popova AYu, Ezhlova EB, Melnikova AA, et al. Experience in Studying Seroprevalence to SARS-CoV-2 Virus in the Population of the Irkutsk Region during COVID-19 Outbreak. Problemy osobo opasnykh infektsij. 2020;3:106-113. (In Russ.). https://doi.org/10.21055/0370-1069-2020-3-106-113
  29. Moghadas SM, Vilches TN, Zhang K, et al. Evaluation of COVID-19 vaccination strategies with a delayed second dose. PLoS Biology. 2021;19(4): e3001211. https://doi.org/10.1371/journal.pbio.3001211
  30. Acuña-Zegarra MA, Díaz-Infante S, Baca-Carrasco D, Olmos-Liceaga D. COVID-19 optimal vaccination policies: A modeling study on efficacy, natural and vaccine-induced immunity responses. Mathematical Biosciences. 2021;337:108614. https://doi.org/10.1016/j.mbs.2021.108614
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.